Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Matinas BioPharma Holdings Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MTNB
American
8731
https://www.matinasbiopharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Matinas BioPharma Holdings Inc
Q4 2023 Matinas BioPharma Holdings Inc Earnings Call
- Mar 28th, 2024 10:46 am
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
- Mar 27th, 2024 8:05 pm
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
- Mar 25th, 2024 12:00 pm
Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?
- Mar 22nd, 2024 4:37 pm
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
- Mar 22nd, 2024 1:15 pm
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
- Mar 22nd, 2024 10:30 am
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
- Feb 26th, 2024 1:00 pm
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
- Feb 20th, 2024 12:30 pm
Matinas BioPharma to Present at Biotech Showcase 2024
- Jan 3rd, 2024 12:00 pm
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
- Dec 27th, 2023 12:30 pm
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
- Dec 21st, 2023 12:30 pm
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call Transcript
- Nov 10th, 2023 6:15 pm
12 Best Day Trading Stocks To Buy
- Nov 9th, 2023 1:52 pm
Q3 2023 Matinas BioPharma Holdings Inc Earnings Call
- Nov 9th, 2023 1:41 pm
Matinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business Progress
- Nov 8th, 2023 11:42 pm
Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
- Nov 8th, 2023 9:05 pm
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
- Nov 7th, 2023 12:30 pm
Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
- Nov 1st, 2023 11:00 am
Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
- Oct 11th, 2023 11:30 am
Matinas BioPharma to Present at Two Investment Conferences in October 2023
- Sep 28th, 2023 11:00 am
Scroll